Charlotte Wagner

1 month ago | nature.com | James Davis |Mikhaila Rice |Kelley Julian |Charlotte Wagner |Shebli Atrash |Jack Khouri | +1 more

TO THE EDITOR:Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by the activation of T-cells and is commonly seen in patients receiving immune effector cell therapies such as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) which target varying tumor antigens such as CD19, CD20, B-cell maturation antigen (BCMA), or GPRC5D depending on the type of malignancy.

Apr 11, 2024 | nature.com | Aimaz Afrough |Doris Hansen |Surbhi Sidana |Lauren C. Peres |Danai Dima |Joseph McGuirk | +6 more

Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [1]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [2].

Aug 9, 2023 | nature.com | Joseph McGuirk |Charlotte Wagner |James Davis |Lauren C. Peres |Yi Lin |Surbhi Sidana | +1 more

AbstractMost patients with multiple myeloma experience disease relapse after treatment with a B-cell maturation antigen-targeted therapy (BCMA-TT), and data describing outcomes for patients treated with sequential BCMA-TT are limited. We analyzed clinical outcomes for patients infused with standard-of-care idecabtagene vicleucel, an anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, at 11 US medical centers.